NCT04321369View on ClinicalTrials.gov

Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals

CompletedOBSERVATIONAL
Enrollment

530

Participants

Timeline

Start Date

March 9, 2020

Primary Completion Date

March 23, 2020

Study Completion Date

March 23, 2020

Conditions
Infections, RespiratoryFeverCough
Interventions
DIAGNOSTIC_TEST

Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals

This is an operational project. Patients will collect a sample from the tongue, nasal cavity and MT and then clinicians will collect a NP sample from the nostril corresponding to each participant's dominant hand.

Trial Locations (1)

98133

Everett Clinic, Seattle

All Listed Sponsors
collaborator

Quest Diagnostics-Nichols Insitute

INDUSTRY

collaborator

Bill and Melinda Gates Foundation

OTHER

lead

UnitedHealth Group

INDUSTRY

NCT04321369 - Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals | Biotech Hunter | Biotech Hunter